Upfront Treatment of Advanced Stage Follicular Lymphoma - A Case Study of Obinutuzumab in Hong Kong

Upfront Treatment of Advanced Stage Follicular Lymphoma – A Case Study of Obinutuzumab in Hong Kong

There is no excerpt because this is a protected post.

US and Chinese Studies Suggest More Severe Outcomes in COVID-19 Patients with Cancer

More Severe Outcomes in COVID-19 Patients with Cancer

Severe COVID-19 infection does not only bring about patient distress, but also increases public health expenditure in supportive devices such as ventilators. It is necessary to minimise the risk of COVID-19 infection in cancer patients, considering COVID-19 waves are likely to recur regularly and they are the high-risk groups. Personal hygiene measures and COVID-19 vaccination have been demonstrated to be efficacious and should be recommended to cancer patients for lowering the likelihood of hospitalisation, ICU admission and mortality.

Experiences with Patient Blood Management in Hong Kong, and Globally

Experiences with Patient Blood Management in Hong Kong, and Globally

There is no excerpt because this is a protected post.

The-Role-of-Patient-Blood-Management-for-Inflammatory-Bowel-Disease-01

The Role of Patient Blood Management for Inflammatory Bowel Disease

There is no excerpt because this is a protected post.

U.S.-FDA-approved-immunecheckpoint-inhibitors-e1528902398517

US FDA approved immune-checkpoint inhibitors updated 08-Dec-2020

Know all the United States Food and Drug Administration (U.S. FDA) approved immune-checkpoint inhibitors. Members of MediPaper can download the free PPT slides summarising the U.S. FDA approved immune-checkpoint inhibitors and other U.S. FDA approved immunotherapies.

Lower-risk-MDS-patients-benefit-from-novel-drug-imetelstat

Lower-risk MDS patients benefit from novel drug, imetelstat

Myelodysplastic syndromes (MDS) are a heterogenous group of clonal haematopoietic disorders that carry a risk of progression to acute myeloid leukaemia (AML). Patients are stratified into risk groups due to the heterogeneity of the disease, which is also exemplified by median overall survival (OS) of 8.8 years for very low risk, and 0.8 years for very high risk patients. Due to symptoms such as anaemia, supportive red blood cell (RBC) transfusions are needed in 80-90% of patients during their disease course, although RBC dependence has been shown to be an adverse prognostic marker.

Venetoclax FDA approved for CLL and SLL

On 15 May 2019, the FDA approved venetoclax (Venclexta®, AbbVie/Genentech) for the treatment of adult chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) patients.

Ivosidenib FDA-approved as first-line treatment for AML patients with IDH1 mutation

On the 2nd of May 2 2019, the FDA approved ivosidenib (Tibsovo®, Agios) as treatment for newly-diagnosed acute myeloid leukaemia (AML) patients ≥75 years old and AML patients with comorbidities precluding intensive induction chemotherapy. Patients should harbour a susceptible IDH1 mutation, as per the FDA-approved Abbott RealTime™ IDH1 Assay, to be legible for ivosidenib treatment.

KEYNOTE-158-pembrolizumab-in-previously-treated-advanced-cervical-cancer

KEYNOTE-158: pembrolizumab in previously treated advanced cervical cancer

Immunotherapy with programmed death 1 (PD-1) antibody pembrolizumab led to an objective response rate (ORR) of 14.6% in previously treated advanced cervical cancer patients with PD-L1–positive disease, as reported by Chung et al. on behalf of the KEYNOTE-158 investigators in the Journal of Clinical Oncology.

Palbociclib approved for the treatment of male breast cancer 

On 4 April 2019, the US FDA approved palbociclib (Ibrance®, Pfizer) plus aromatase inhibitor or fulvestrant for the treatment of male patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.